Haegerstrand, born 1961, has extensive R&D experience including drug discovery and development as manager at Karolinska Institutet, Astra Pain Control AB and AstraZeneca LLC and within biotech. From year 2000, Anders was CEO and CSO for NeuroNova AB, a leading company in applied stem cell research that brought to protein molecules into Phase I/II clinical studies. The company was later acquired by a listed company, Newron Pharmaceuticals S.p.A., at which Anders was a management team member between 2013 and 2016. Haegerstrand has been a member of Annexin’s board since 2018 and CEO since 2019.
Shareholding in the Company: 350 000 shares, 1 414 761 share option rights series 2020/2023 and 150 000 share option rights serie TO3
Chief Financial Officer
Henrik Palm, born in 1958, comes from the position of CFO of Karo Pharma AB. He has a degree in economics from the University of Gothenburg. Henrik has many years of experience as Business Controller within the Ericsson Group and as CFO for ElektronikGruppen BK AB and Feelgood Svenska AB. Employed since 2019.
Shareholding in the Company: 175 000 shares, 235 758 share option rights series 2020/2023 and 75 000 share option rights serie TO3
MD, PhD, Licensed Physician, Chief Scientific and Medical Officer
Anna Frostegård, born in 1973, is a globally educated Licensed Physician who earned her Doctor of Medicine degree summa cum laude and earned her Doctor of Philosophy degree in Experimental Medicine from Karolinska Instututet. Anna has served as an Assistant Professor at the Unit of Immunology and Chronic Disease and has more than 10 years’ experience in translating academic discoveries into the development of biological drugs. Anna is one of the inventors and co-founder of Annexin Pharmaceuticals. Anna is an expert in Annexin A5, vascular inflammation and cardiovascular diseases. Anna has been serving as Chief Scientific and Medical Officer (CSO/CMO) of Annexin Pharmaceuticals since 2016.
Shareholdings in the Company: 2 873 296 shares indirectly through Frostskog AB and Medirista AB (which own 2 369 296 and 504 000 shares of Annexin respectively) and 1 000 000 share option rights serie TO3 through Frostskog AB
Chief Operating Officer
Susan Suchdev, born in 1972, comes from the position as COO and member of the management team at Klaria. Susan, who has an M.Sc. from Karolinska Institutet in Stockholm, has previously had a long career with project management roles in clinical development projects, including Pfizer, TFS Trial Form Support and Nestlé Health Science. Employed since 2018.
Shareholding in the Company: 60 055 shares and 29 595 share option rights serie TO3